Spots Global Cancer Trial Database for ntrk
Every month we try and update this database with for ntrk cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer | NCT02219711 | Advanced Cancer | MGCD516 | 18 Years - | Mirati Therapeutics Inc. | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | NCT02920996 | Carcinoma, Non-... Solid Tumor | Merestinib | 18 Years - | Dana-Farber Cancer Institute | |
| Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | NCT02920996 | Carcinoma, Non-... Solid Tumor | Merestinib | 18 Years - | Dana-Farber Cancer Institute | |
| A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study | NCT04010240 | Metastatic Soli... | Retrospective c... | 1 Month - | Institut Bergonié | |
| Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors | NCT04901806 | Solid Tumor, Ad... Brain Tumor, Pr... Desmoplastic Sm... | PBI-200 | 18 Years - | Pyramid Biosciences | |
| A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study | NCT04010240 | Metastatic Soli... | Retrospective c... | 1 Month - | Institut Bergonié | |
| Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion | NCT04557813 | NTRK Family Gen... | 18 Years - | iOMEDICO AG | ||
| Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | NCT02650401 | Solid Tumors CNS Tumors | Entrectinib | 0 Years - 18 Years | Hoffmann-La Roche | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors | NCT04901806 | Solid Tumor, Ad... Brain Tumor, Pr... Desmoplastic Sm... | PBI-200 | 18 Years - | Pyramid Biosciences | |
| Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion | NCT04557813 | NTRK Family Gen... | 18 Years - | iOMEDICO AG | ||
| Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | NCT02650401 | Solid Tumors CNS Tumors | Entrectinib | 0 Years - 18 Years | Hoffmann-La Roche | |
| Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors | NCT02675491 | Advanced Solid ... | DS-6051b | 20 Years - | Daiichi Sankyo | |
| Study of FCN-011 in Patients With Advanced Solid Tumor（Phase I）and NTRK Fusion Positive Advanced Solid Tumor （Phase II） | NCT04687423 | Advanced Solid ... | FCN-011 | 16 Years - | Fochon Pharmaceuticals, Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
